Natera (NTRA) Stock Forecast, Price & News

Natera (NASDAQ:NTRA) Frequently Asked Questions

Is Natera a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Natera stock.
View analyst ratings for Natera or view top-rated stocks.

When is Natera's next earnings date?

Natera is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Natera.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) issued its quarterly earnings results on Friday, May, 6th. The medical research company reported ($1.45) earnings per share for the quarter, beating the consensus estimate of ($1.50) by $0.05. The medical research company earned $194.13 million during the quarter, compared to analysts' expectations of $176.61 million. Natera had a negative trailing twelve-month return on equity of 96.99% and a negative net margin of 81.90%. The business's quarterly revenue was up 27.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.74) earnings per share.
View Natera's earnings history.

What guidance has Natera issued on next quarter's earnings?

Natera updated its FY 2022 earnings guidance on Monday, May, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $790.00 million-$810.00 million, compared to the consensus revenue estimate of $779.92 million.

What price target have analysts set for NTRA?

10 brokerages have issued 1-year price targets for Natera's shares. Their forecasts range from $54.00 to $160.00. On average, they expect Natera's stock price to reach $97.64 in the next twelve months. This suggests a possible upside of 137.0% from the stock's current price.
View analysts' price targets for Natera or view top-rated stocks among Wall Street analysts.

Who are Natera's key executives?

Natera's management team includes the following people:

• Dr. Matthew Rabinowitz Ph.D., Co-Founder & Exec. Chairman (Age 49, Pay $502.21k) (LinkedIn Profile)
• Mr. Steven Leonard Chapman, CEO, Pres & Director (Age 43, Pay $925.59k)
• Mr. Michael B. Brophy M.B.A., Chief Financial Officer (Age 42, Pay $661.5k)
• Mr. Robert A. Schueren, Chief Operating Officer (Age 60, Pay $706.72k) (LinkedIn Profile)
• Mr. Daniel Rabinowitz L.L.M., LL.M., Sec. & Chief Legal Officer (Age 53, Pay $557.47k) (LinkedIn Profile)
• Mr. Jonathan Sheena M.Eng., Co-Founder & Director (Age 49) (LinkedIn Profile)
• Ms. Olesya A. Anisimova CPA, Chief Accounting Officer
• Mr. Rishi Kacker, Chief Technology Officer
• Mr. Eric A. Evans, Chief Scientific Officer
• Mr. Phil Grinnell, VP of Sales

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera CEO Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among Natera's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Natera's key competitors?

Some companies that are related to Natera include Exact Sciences (EXAS), Guardant Health (GH), Elekta AB (publ) (EKTAY), Fulgent Genetics (FLGT), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Invitae (NVTA), Castle Biosciences (CSTL), Viridian Therapeutics (VRDN), Burning Rock Biotech (BNR), DermTech (DMTK), Personalis (PSNL), Renalytix (RNLX) and Biora Therapeutics (BIOR).
View all of NTRA's competitors.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Who are Natera's major shareholders?

Natera's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.08%), JPMorgan Chase & Co. (5.20%), State Street Corp (2.94%), Invesco Ltd. (2.41%), RTW Investments LP (1.99%) and Sculptor Capital LP (1.67%). Company insiders that own Natera stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends for Natera.

Which institutional investors are selling Natera stock?

NTRA stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., American Century Companies Inc., Invesco Ltd., Lord Abbett & CO. LLC, Farallon Capital Management LLC, Brown Advisory Inc., Jennison Associates LLC, and Gilder Gagnon Howe & Co. LLC. Company insiders that have sold Natera company stock in the last year include Daniel Rabinowitz, Herm Rosenman, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren, Rowan E Chapman, Steven Leonard Chapman, and Todd C Cozzens.
View insider buying and selling activity for Natera or view top insider-selling stocks.

Which institutional investors are buying Natera stock?

NTRA stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., State Street Corp, Kynam Capital Management LP, Bank of Nova Scotia, Assenagon Asset Management S.A., Kornitzer Capital Management Inc. KS, Frontier Capital Management Co. LLC, and Blue Water Life Science Advisors LP. Company insiders that have bought Natera stock in the last two years include James Healy, Matthew Rabinowitz, Patrick J Donovan, and Roelof Botha.
View insider buying and selling activity for Natera or or view top insider-buying stocks.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $41.19.

How much money does Natera make?

Natera has a market capitalization of $3.97 billion and generates $625.49 million in revenue each year. The medical research company earns $-471.72 million in net income (profit) each year or ($5.880010) on an earnings per share basis.

How many employees does Natera have?

Natera employs 2,670 workers across the globe.

What is Natera's official website?

The official website for Natera is www.natera.com.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at (650) 249-9090 or via email at [email protected].